Abstracts tagged "Biomarkers"

Abstract Number: 2661 • ACR Convergence 2024
Changes in Krebs Von Den Lungen 6 Levels (∆KL6) Predict Fibrosing Progression of Interstitial Lung Disease in Patients with an Underlying Connective Tissue Disease (CTD-ILD)
Fredeswinda Romero-Bueno¹, María Carmen Vegas-Sánchez², lydia Abasolo Alcazar³, Mª Jesus Rodriguez Nieto², Cristina Vadillo-Font⁴, M Asuncion Nieto⁵, Laura Cebrián⁶, Belén López-Muñiz⁶, Jesus Loarce Martos⁷, Juan Rigual⁸, hildegarda Godoy Tundidor⁹, Rosalía Laporta¹⁰, Irene Llorente-Cubas¹¹, Gema Bonilla¹², Luis Gomez Carrera¹³, Rosario García-Vicuña¹⁴, Ana Jaureguizar⁷, Jose Luis Morell Hita⁷, Claudia Valenzuela¹⁵ and Olga Sánchez-Pernaute¹⁶, and the NEREA Study group for Autoimmune ILD, ¹Hospital Universitario Fundación Jiménez Díaz and IIS-FJD. Autonomous University of Madrid, Madrid, Spain, ²Hospital Universitario Fundación Jiménez Díaz and IIS-FJD, Madrid, Spain, ³IdISSC. HCSC, Madrid, Spain, ⁴Hospital Clinico S Carlos, Madrid, Spain, ⁵Hospital Clínico San Carlos, Madrid, Madrid, Spain, ⁶Hospital Universitario Infanta Leonor, Madrid, Spain, ⁷Hospital Universitario Ramón y Cajal - IRYCIS, Madrid, Spain, ⁸Ramón y Cajal University Hospital, Madrid, Madrid, Spain, ⁹Servicio de Reumatología, Hospital Universitario Puerta de Hierro Majadahonda, IDIPHISA , Madrid, Madrid, Spain, ¹⁰Hospital Universitario Puerta de Hierro, Madrid, Spain, ¹¹Hospital Universitario de La Princesa, Madrid, Spain, ¹²H. Universitario La Paz, Madrid, Spain, ¹³Hospital Universitario La Paz, Madrid, Spain, ¹⁴Hospital Universitario de la Princesa, Madrid, Madrid, Spain, ¹⁵Hospital Universitario La Princesa, Madrid, Spain, ¹⁶Department of Rheumatology and Joint and Bone Research Unit. Hospital Universitario Fundación Jiménez Díaz and IIS-FJD. Autonomous University of Madrid, Madrid, Spain
Background/Purpose: Krebs von den Lungen-6 (KL6) is a mucin-1 glycoprotein produced by type 2 alveolar epithelial cells , which increase at peripheral blood show a…
Abstract Number: 0054 • ACR Convergence 2024
Supernatants from Macrophages Stimulated with Citrullinated and MAA-Modified Fibrinogen Contain PDGF-BB and TGF-b and Upregulate Fibrotic Markers in Human Lung Fibroblasts
Nozima Aripova¹, Michael Duryee¹, Bryant England¹, Carlos Hunter¹, Lauren Klingemann¹, Nigina Aripova², Amy Nelson¹, Jill Poole¹, Dawn Katafiasz¹, Kristina Bailey¹, Geoffrey Thiele¹ and Ted Mikuls¹, ¹University of Nebraska Medical Center, Omaha, NE, ²WUSTL, St. Louis, MO
Background/Purpose: Lung tissues from patients with rheumatoid arthritis-associated interstitial lung disease (RA-ILD) have greater levels of malondialdehyde-acetaldehyde adducts (MAA) that co-localize with citrullinated (CIT) and…
Abstract Number: 0382 • ACR Convergence 2024
Comparative Analysis of Tear-based S100 Proteins, Cytokines, and Chemokines Levels in Juvenile Idiopathic Arthritis Associated-uveitis: Insights into Eye Laterality and Severity of Ocular Inflammation
Ilaria Maccora¹, Mariia Pavlenko², Jackeline Rodriguez-Smith³, Amy Cassedy⁴, Mekibib Altaye⁵, hermine brunner⁶, Alexandra Duell⁵, Alexei Grom⁵, Theresa Hennard⁷, Virginia Miraldi Utz⁵, Najima Mwase⁵, Megan Quinlan-Waters⁵, grant schulert⁵, Alyssa Sproles⁸, Jessica Shantha⁹, Sunil K Srivastava¹⁰, Sherry Thornton⁸, Steven Yeh¹¹ and sheila Angeles-Han¹², ¹?PhD student, in the Area of Drugs and Innovative Treatments, NeuroFARBA Department, University of Florence. Meyer Children's Hospital, Florence Italy, Firenze, Florence, Italy, ²Division of Rheumatology, Cincinnati Children`s Hospital Medical Center, Cincinnati, OH, ³Division of Rheumatology, Cincinnati Children’s Hospital Medical Center and Department of Pediatrics, University of Cincinnati, Cincinnati, OH, Cincinnati, OH, ⁴Division of Biostatistics and Epidemology, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, Cincinnati, OH, ⁵Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ⁶Cincinnati Children's Hospital Medical Center, University of Cincinnati College of Medicine, Cincinnati, OH, ⁷Cincinnati Children's Hospital and Medical Center, Cincinnati, OH, ⁸Cincinnati Children's Hospital, Cincinnati, ⁹UCSF/Proctor Foundation, San Francisco, IL, ¹⁰Cole Eye Institute, Cleveland Clinic;, Cleveland, OH, ¹¹Truhlsen Eye Institute, University of Nebraska Medical Center., Nebraska, NE, ¹²Cincinnati Children's Hospital, Cincinnati, OH
Background/Purpose: Juvenile idiopathic arthritis-associated uveitis (JIA-U) is an ocular disease that can be unilateral or bilateral. Measurement of ocular inflammation is performed by ophthalmic examination…
Abstract Number: 0505 • ACR Convergence 2024
UseofaMolecularSignatureResponseClassifiertoPredictInadequateResponsetoTNFiResultsinFewer Patients Prescribed TNFi
George Karpouzas¹, Lixia Zhang², Mark Zielinski², Brian Cheng² and Sherry Guardiano³, ¹Harbor-UCLA Medical Center, Torrance, CA, ²Scipher Medicine Corporation, Waltham, MA, ³Scipher Medicine Corporation, Keene, NH
Background/Purpose: Tumor necrosis factor inhibitors (TNFi) are generally the first class of biologic disease modifying anti-rheumatic drugs (DMARDs) prescribed for rheumatoid arthritis (RA) patients with…
Abstract Number: 0643 • ACR Convergence 2024
Using FDG PET Brain Scans and Deep Learning Analyses to Identify a Specific Network Correlated with Cognitive Impairment in SLE
Nha Nguyen¹, An Vo¹, Chris Tang¹, Erik Anderson², Cynthia Aranow², Betty Diamond³, David Eidelberg¹ and Meggan Mackay⁴, ¹Feinstein Institutes, Manhasset, NY, ²Feinstein Institutes for Medical Research, New York, NY, ³The Feinstein Institutes for Medical Research, Manhasset, NY, ⁴Feinstein Institutes for Medical Research, Manhasset, NY
Background/Purpose: Cognitive impairment (CI) is a debilitating, untreatable problem for up to 80% of individuals with SLE and human and mouse data suggest multiple SLE-related…
Abstract Number: 0799 • ACR Convergence 2024
Peripheral Biomarker Signatures and a Genetic Risk Score Improve the Identification of RA-ILD Beyond Clinical Risk Factors
Austin Wheeler¹, Thomas Riley², Joshua Baker³, Yangyuna Yang¹, Punyasha Roul⁴, Katherine Wysham⁵, grant Cannon⁶, Gary Kunkel⁷, Gail Kerr⁸, Dana Ascherman⁹, Paul Monach¹⁰, Andreas Reimold¹¹, Jill Poole¹, Tony Merriman¹², Ted Mikuls¹ and Bryant England¹, ¹University of Nebraska Medical Center, Omaha, NE, ²Hopsital of the University of Pennsylvania, Philadelphia, PA, ³University of Pennsylvania, Philadelphia, PA, ⁴UNMC, Omaha, NE, ⁵VA PUGET SOUND/UNIVERSITY OF WASHINGTON, Seattle, WA, ⁶University of Utah and Salt Lake City VA, Salt Lake City, UT, ⁷University of Utah and George E Wahlen VAMC, Salt Lake City, UT, ⁸Washington DC VAMC/Georgetown and Howard Universities, Washington, DC, ⁹Division of Rheumatology and Clinical Immunology, University of Pittsburgh Medical Center, Pittsburgh, PA, ¹⁰VA Boston Healthcare System, Boston, MA, ¹¹Dallas VA Medical Center, Dallas, TX, ¹²University of Alabama at Birmingham, Homewood, AL
Background/Purpose: Rheumatoid arthritis-associated interstitial lung disease (RA-ILD) is an extra-articular manifestation of RA that causes substantial morbidity and mortality. Despite the paucity of known risk…
Abstract Number: 0899 • ACR Convergence 2024
Proteomic Insights into JAK Inhibitor Therapeutic Response in Rheumatoid Arthritis
Ting-Shuan Wu¹ and Yi-Ming Chen², ¹Chung Shan Medical University, Taichung, Taiwan (Republic of China), ²Taichung Veterans General Hospital, Taiwan, Taichung, Taiwan (Republic of China)
Background/Purpose: Rheumatoid arthritis (RA) is a common and complex inflammatory polyarthritis. Janus kinase inhibitors (JAKi) have shown superior efficacy compared to traditional treatments, but predictors…
Abstract Number: 1191 • ACR Convergence 2024
Discordant Associations Among Chronological and Biological Age with Multi-joint Osteoarthritis and Symptom Burden: The Johnston County Health Study
Liubov Arbeeva¹, Yvonne Golightly², Cameron Kurz³, Matlock Jeffries⁴, Virginia Kraus⁵, Richard Loeser⁶, Duncan Lascelles⁷ and Amanda Nelson³, ¹University of North Carolina, Chapel Hill, Carrboro, NC, ²University of Nebraska Medical Center, Omaha, NE, ³University of North Carolina at Chapel Hill, Chapel Hill, NC, ⁴Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁵Duke University, Durham, NC, ⁶University of North Carolina, Chapel Hill, NC, ⁷North Carolina State University, Raleigh, NC
Background/Purpose: Biological age (BA) may be superior to chronological age (CA) in predicting mortality and age-related conditions such as diabetes and cognitive/functional decline (PMID35715611), as…
Abstract Number: 1463 • ACR Convergence 2024
Investigation of the Cardiometabolic-related Mechanism of Action of Apremilast Through Plasma Proteomics Profiling of Patients with Psoriasis or Psoriatic Arthritis from Three Phase 3 Studies
A. Francesca Setiadi¹, Maggie Burhans², Xuguang Hu², Stephen Colgan³, Kim Notari², Marcia C. Teixeira dos Santos², Apostolos Kontzias², Sue Cheng² and Nehal Mehta⁴, ¹Amgen Inc., South San Francisco, CA, ²Amgen Inc., Thousand Oaks, CA, ³Amgen, Halton Hills, ON, Canada, ⁴The George Washington University School of Medicine, Washington, DC
Background/Purpose: Psoriasis (PsO) and psoriatic arthritis (PsA) are associated with higher rates of obesity and cardiometabolic complications. Apremilast (APR) is an inhibitor of phosphodiesterase 4,…
Abstract Number: 1685 • ACR Convergence 2024
The Renal Activity Index for Lupus (RAIL) Identifies Active Renal Disease in SLE Patients and Its Longitudinal Score Associates with Achievement of Renal Responses in Lupus Nephritis
Minal Aundhia¹, Jinqi Liu², Ellen Cody³, James Rose⁴, Angela Merritt¹, Megan Quinlan-Waters¹, Alyssa Sproles⁵, Sherry Thornton⁵, Prasad Devarajan⁴, Bin Huang⁶ and hermine brunner⁷, ¹Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ²Bristol Myers Squibb, Princeton, NJ, ³Children's Wisconsin, Milwaukee, ⁴Cincinnati Children's Hospital Medical Center, Cincinnati, ⁵Cincinnati Children's Hospital, Cincinnati, ⁶Cincinnati Children's Hospital Medical Center, University of Cincinnati College of Medicine, Cinciannati, OH, ⁷Cincinnati Children's Hospital Medical Center, University of Cincinnati College of Medicine, Cincinnati, OH
Background/Purpose: Lupus Nephritis (LN) confers a poor prognosis, and there is a lack of effective non-invasive tests to assess disease activity and treatment response. We…
Abstract Number: 2010 • ACR Convergence 2024
The Influence of Treat-to-target Urate Lowering Therapy and Anti-inflammatory Prophylaxis on Circulating Measures of Inflammation in Gout
Austin Wheeler¹, Tanner Ourada², Michael Duryee¹, Bryant England¹, Richard Reynolds³, James O'Dell¹, Jeff Newcomb¹, Michael Pillinger⁴, Robert Terkeltaub⁵, Ryan Ferguson⁶, Mary Brophy⁶, Tony Merriman⁷ and Ted Mikuls¹, ¹University of Nebraska Medical Center, Omaha, NE, ²University of Nebraska-Medical Center: College of Medicine, Omaha, NE, ³University of Alabama at Birmingham, Birmingham, AL, ⁴New York University Grossman School of Medicine, New York,, NY, ⁵Retired, San Diego, CA, ⁶Veterans Affairs, Boston, MA, ⁷University of Alabama at Birmingham, Homewood, AL
Background/Purpose: Gout is the most common inflammatory arthritis worldwide and is associated with substantial cardiometabolic morbidity and mortality. In the STOP Gout trial (O’Dell JR…
Abstract Number: 2267 • ACR Convergence 2024
A Novel Blood-based Assay That Predicts Clinical Response to TNFα Inhibitors or Janus Kinase Inhibitors in Patients with Rheumatoid Arthritis
Maggie Louie¹, Signe Fransen², Katherine Dilger¹, Kevin Lai¹, Diana Abdueva³, David Chernoff⁴ and Jeffrey Curtis⁵, ¹Aqtual Inc, Hayward, CA, ²Aqtual Inc., sf, CA, ³Aqtual Inc., Hayward, CA, ⁴SetPoint Medical, Sausalito, CA, ⁵University of Alabama at Birmingham, Hoover, AL
Background/Purpose: Current rheumatoid arthritis (RA) treatments, including TNFa inhibitors (TNFi) and JAK inhibitors (JAKi), have transformed the management of RA by controlling symptoms and slowing…
Abstract Number: 2456 • ACR Convergence 2024
High Levels of Circulating IFNα Are Associated with Increased Mortality in Patients with Diffuse Cutaneous Systemic Sclerosis
François Maillet¹, Carine Schmidt¹, Vincent Bondet², Alexandre Bense¹, Darragh Duffy³, Luc Mouthon¹, Mathieu Paul Rodero⁴ and Benjamin Chaigne⁵, ¹AP HP, Paris, France, ²INSERM PAsteur Institute, Paris, France, ³Inserm Pasteur Institue, Paris, France, ⁴Université Paris CIté, Laboratoire de Chimie et de Biochimie Pharmacologiques et Toxicologiques, Faculté des Saint-Pères, Paris, France, ⁵Service de Médecine Interne, Centre de Référence Maladies Systémiques Autoimmunes et Autoinflammatoires Rares d'Ile de France de l’Est et de l’Ouest, Hôpital Cochin, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, Ile-de-France, France
Background/Purpose: Systemic sclerosis (SSc) is a connective tissue disease characterized by skin and organ fibrosis, autoimmunity, and vasculopathy. Although its pathophysiology remains unclear, recent data…
Abstract Number: 2668 • ACR Convergence 2024
Do Levels of anti-Jo1 Autoantibodies Have a Prognostic Role? Longitudinal Assessment of anti-Jo1 and HisRS Protein Levels in a Cohort of anti-Jo1 Positive Patients with Anti-synthetase Syndrome
Silvia Cavalli¹, Fabricio Espinosa-Ortega², Ryan A. Adams³, Lauren Guy³, Charlotta Preger⁴, Càtia Fernandes-Cerqueira⁵, Roberto Caporali⁶, Ingrid Lundberg⁷ and Antonella Notarnicola⁸, ¹University of Milan, Milan, Milan, Italy, ²Division of Rheumatology, Department of Medicine, Solna, Karolinska Institutet; Department of Gastro, Dermatology and Rheumatology, Karolinska University Hospital, Stockholm, Sweden, Stockholm, Stockholms Lan, Sweden, ³aTyr Pharma, 3545 John Hopkins Court, Suite 250, San Diego, CA, ⁴Division of Rheumatology, Department of Medicine, Solna, Karolinska Institutet;5Structural Genomics Consortium, Stockholm, Sweden, Stockholm, Stockholms Lan, Sweden, ⁵4Dcell, Montrueil, Ile-de-France, France, ⁶Department of Clinical Sciences and Community Health, University of Milan, and Department of Rheumatology and Medical Sciences, ASST Gaetano Pini-CTO, Milan, Italy, ⁷Karolinska Universitetssjukhuset, Karolinska Institutet, Stockholm, Sweden, ⁸Karolinska University Hospital and Karolinska Institutet, Stockholm, Stockholms Lan, Sweden
Background/Purpose: The anti-Jo1 autoantibody (aJo1), targeting the histidyl-tRNA synthetase (HisRS) protein, is the most common diagnostic biomarker of the anti-synthetase syndrome (ASSD). So far, conflicting…
Abstract Number: 0056 • ACR Convergence 2024
Association of Soluble Immune Checkpoint Proteins with the Risk of Developing RA in ACPA-positive At-risk Individuals
Ryo Motoyama¹, Shohei Nakamura¹, Eisuke Inoue², Hideto Takada³, Masayoshi Harigai⁴ and Yuko okamoto¹, ¹Tokyo Women's Medical University, Tokyo, Japan, ²Showa University, Tokyo, Japan, ³Tokyo Women's Medical University, Denver, CO, ⁴International University of Health and Welfare, Tokyo, Japan
Background/Purpose: ACPA+ individuals without inflammatory arthritis are considered as being in an at-risk state of RA, although further factors are needed to identify individuals with…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.